Literature DB >> 17692012

Modulation of ion channels in pulmonary arterial hypertension.

Christelle Guibert1, Roger Marthan, Jean-Pierre Savineau.   

Abstract

Pulmonary arterial hypertension (PAH) is a disease characterized by a progressive increase in pulmonary arterial pressure leading to right ventricular hypertrophy, right heart failure and ultimately to death. PAH is a disease of small pulmonary arteries inducing vascular narrowing leading to a progressive increase in pulmonary vascular resistance. The therapeutic means that improve PAH are still very limited and are too often restricted to heart/lungs transplantation. Numerous forms of pulmonary hypertension exist. Although it is still unclear as to all types of PAH share a common pathogenesis, it is generally admitted that pulmonary vasoconstriction and remodelling of the arterial wall are key events. In this review, we discuss pulmonary artery smooth muscle cells (PASMC) ion channels implication in both phenomena and we examine whether variations in expression and/or the activity of these channels can contribute to the development of PAH with special attention to K(+), Cl(-) and voltage- and non voltage-activated Ca(2+) channels. For each family of ion channels, we describe their implication in the control of both membrane potential and resting cytosolic calcium concentration which are key parameters of PASMC in PAH. We also provide evidence for an implication of these channels in not only vasoconstriction but also proliferation and/or decreased apoptosis of PASMC, phenomena which contribute to remodelling of pulmonary arterial wall. In this respect, PAH may be considered as form of vascular "channelopathy". Finally, we present examples of some substances acting on ion channels and thus potentially constituting innovative therapeutic approaches of PAH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692012     DOI: 10.2174/138161207781368585

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

1.  Contribution of calcium-activated chloride channel to elevated pulmonary artery pressure in pulmonary arterial hypertension induced by high pulmonary blood flow.

Authors:  Kai Wang; Chuansi Chen; Jianfa Ma; Jinquan Lao; Yusheng Pang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  NiONP-Induced Oxidative Stress and Mitochondrial Impairment in an In Vitro Pulmonary Vascular Cell Model Mimicking Endothelial Dysfunction.

Authors:  Ophélie Germande; Thomas Ducret; Jean-Francois Quignard; Juliette Deweirdt; Véronique Freund-Michel; Marie-Hélène Errera; Guillaume Cardouat; Pierre Vacher; Bernard Muller; Patrick Berger; Christelle Guibert; Magalie Baudrimont; Isabelle Baudrimont
Journal:  Antioxidants (Basel)       Date:  2022-04-26

3.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

4.  Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.

Authors:  Myriam Iglewski; Stephen R Grant
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

5.  Transient receptor potential (TRP) channels as a therapeutic target for intervention of respiratory effects and lethality from phosgene.

Authors:  Devon Andres; Brian Keyser; Betty Benton; Ashley Melber; Dorian Olivera; Wesley Holmes; Danielle Paradiso; Dana Anderson; Radharaman Ray
Journal:  Toxicol Lett       Date:  2015-11-10       Impact factor: 4.372

6.  Role of the gap junctions in the contractile response to agonists in pulmonary artery from two rat models of pulmonary hypertension.

Authors:  Marie Billaud; Diana Dahan; Roger Marthan; Jean-Pierre Savineau; Christelle Guibert
Journal:  Respir Res       Date:  2011-03-17

7.  Effects of FW2 Nanoparticles Toxicity in a New In Vitro Pulmonary Vascular Cells Model Mimicking Endothelial Dysfunction.

Authors:  J Deweirdt; T Ducret; J-F Quignard; V Freund-Michel; S Lacomme; E Gontier; B Muller; R Marthan; C Guibert; I Baudrimont
Journal:  Cardiovasc Toxicol       Date:  2021-09-15       Impact factor: 3.231

8.  The Xanthine Derivative KMUP-1 Attenuates Serotonin-Induced Vasoconstriction and K⁺-Channel Inhibitory Activity via the PKC Pathway in Pulmonary Arteries.

Authors:  Zen-Kong Dai; Yu-Wei Liu; Jong-Hau Hsu; Jwu-Lai Yeh; Ing-Jun Chen; Jiunn-Ren Wu; Bin-Nan Wu
Journal:  Int J Biol Sci       Date:  2015-04-25       Impact factor: 6.580

9.  Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series).

Authors:  Benoît Ranchoux; Lloyd D Harvey; Ramon J Ayon; Aleksandra Babicheva; Sebastien Bonnet; Stephen Y Chan; Jason X-J Yuan; Vinicio de Jesus Perez
Journal:  Pulm Circ       Date:  2017-12-28       Impact factor: 3.017

10.  Iptakalim, a novel ATP-sensitive potassium channel opener, inhibits pulmonary arterial smooth muscle cell proliferation by downregulation of PKC-α.

Authors:  Xiangrong Zuo; Feng Zong; Hui Wang; Qiang Wang; Weiping Xie; Hong Wang
Journal:  J Biomed Res       Date:  2011-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.